Qualigen Therapeutics (Qualigen Therapeutics) EBIT : $-11.98 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics EBIT?

Qualigen Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.92 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.98 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Qualigen Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -286.64%. Qualigen Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Qualigen Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -461.30%.

Qualigen Therapeutics EBIT Historical Data

The historical data trend for Qualigen Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics EBIT Chart

Qualigen Therapeutics Annual Data

Trend

Mar20

Dec21

Dec22

Dec23

EBIT

-1.50

-22.66

-13.85

-10.96

Qualigen Therapeutics Quarterly Data
	Jun19	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial													-2.53	-3.73	-3.55	-2.78	-1.92

Competitive Comparison of Qualigen Therapeutics's EBIT

For the Biotechnology subindustry, Qualigen Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qualigen Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's EV-to-EBIT falls into.

Qualigen Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.98 Mil.

Qualigen Therapeutics (NAS:QLGN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Qualigen Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-9.096 * ( 1 - 0.2% )	/	( (3.984	+	2.35)	/ 2 )
=	-9.077808	/	3.167
=	-286.64 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.316	-	2.839	-	( 2.074	-	max(0, 5.957	-	3.45	+	2.074	))
=	3.984

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.033	-	2.653	-	( 0.402	-	max(0, 4.137	-	1.167	+	0.402	))
=	2.35

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Qualigen Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.696	/	( ( (0 + max(-3.984, 0))	+	(0 + max(-2.073, 0)) )	/	2 )
=	-7.696	/	( ( 0	+	0 )	/	2 )
=	-7.696	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.141)	-	(2.839	+	0	+	2.286)
=	-3.984

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.765)	-	(2.653	+	0	+	0.185)
=	-2.073

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Qualigen Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-11.98	/	2.597
	=	-461.30 %

Qualigen Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualigen Therapeutics (Qualigen Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (NAS:QLGN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

7R9:Germany

Address

2042 Corte del Nogal, Suite B, Carlsbad, CA, USA, 92011

Website

https://www.qualigeninc.com

Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. It is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. The Company has viewed its operations and managed its business in one segment operating mainly within the United States and Israel.

Executives

Michael S. Poirier	director, officer: Chairman, President and CEO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Amy S. Broidrick	director	1440 VALLE GRANDE, ESCONDIDO CA 92025
Kurt H Kruger	director	100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035
Tariq Arshad	officer: SVP/Chief Medical Officer	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Christopher L. Lotz	officer: Vice President of Finance, CFO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211
Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Richard A. David	director	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Wajdi Abdul-ahad	officer: VP, R&D, CSO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Shishir K. Sinha	officer: VP of Operations	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Sekisui Diagnostics, Llc	10 percent owner	1 WALL STREET, BURLINGTON MA 01803
Matthew E Korenberg	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Noah Doyle	director	C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
John W Beck	officer: Chief Financial Officer	C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Jeffrey S Benjamin	officer: VP of Finance	3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
William M. Merino	director	C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067